Ageliki Karatza | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Ageliki Karatza | Clinical Trials | Best Researcher Award

University of Patras Medical School | Greece

Prof. Dr. Ageliki Karatza is a distinguished figure in the field of Paediatrics and Paediatric Cardiology, recognized for her exceptional academic achievements, clinical expertise, and research contributions spanning decades. Her journey began with her admission to the University of Patras Medical School through highly competitive national examinations, where she graduated with one of the top degrees in her class. Following her graduation, she completed her rural medical service before pursuing specialization in General Paediatrics, earning her board certification after extensive training and rigorous examinations.Her dedication to advancing paediatric care led her to prominent institutions in London, including Imperial College, Hammersmith and Queen Charlotte’s Hospitals, and the Royal Brompton Hospital, where she gained substantial clinical and research experience in Paediatric and Perinatal Cardiology. Her fellowship and registrar positions in Neonatal and Paediatric Cardiology enabled her to develop expertise in managing complex cardiovascular conditions in neonates, infants, and children. Upon returning to Greece, she held key positions in academic medicine at the University of Patras Medical School, progressing through roles as Clinical Lecturer, Senior Lecturer, Associate Professor, and ultimately achieving the rank of Professor in Paediatrics-Paediatric Cardiology.In addition to her teaching responsibilities, she has been instrumental in organizing and delivering undergraduate and postgraduate education, serving as a tutor in multiple master’s programs and teaching medical students and trainees at various levels. Her role as the ERASMUS representative in Paediatrics has facilitated international academic collaborations and student exchanges, strengthening the global reach of the University of Patras Medical School. Clinically, she has been responsible for the Paediatric Cardiology outpatient clinic, providing daily consultations and urgent care services for the entire Southwestern Greece region, ensuring that paediatric patients receive timely and specialized cardiac care.

Profile: Google Scholar

Featured Publications

Karatza, A. A., Wolfenden, J. L., Taylor, M. J. O., Wee, L., Fisk, N. M., & Gardiner, H. M. (2002). Influence of twin-twin transfusion syndrome on fetal cardiovascular structure and function: Prospective case–control study of 136 monochorionic twin pregnancies. Heart, 88(3), 271–277.

Karatza, A. A., Bush, A., & Magee, A. G. (2005). Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. International Journal of Cardiology, 100(2), 267–273.

Davlouros, P. A., Karatza, A. A., Gatzoulis, M. A., & Shore, D. F. (2004). Timing and type of surgery for severe pulmonary regurgitation after repair of tetralogy of Fallot. International Journal of Cardiology, 97, 91–101.

Gardiner, H. M., Taylor, M. J. O., Karatza, A., Vanderheyden, T., Huber, A., … (2003). Twin-twin transfusion syndrome: The influence of intrauterine laser photocoagulation on arterial distensibility in childhood. Circulation, 107(14), 1906–1911.

Fouzas, S., Karatza, A. A., Davlouros, P. A., Chrysis, D., Alexopoulos, D., … (2014). Neonatal cardiac dysfunction in intrauterine growth restriction. Pediatric Research, 75(5), 651–657.

Karatza, A. A., Giannakopoulos, I., Dassios, T. G., Belavgenis, G., Mantagos, S. P., … (2011). Periconceptional tobacco smoking and isolated congenital heart defects in the neonatal period. International Journal of Cardiology, 148(3), 295–299.

Tsintoni, A., Dimitriou, G., & Karatza, A. A. (2020). Nutrition of neonates with congenital heart disease: Existing evidence, conflicts, and concerns. The Journal of Maternal-Fetal & Neonatal Medicine, 33(14), 2487–2492.

Anthracopoulos, M., Karatza, A., Liolios, E., Triga, M., Triantou, K., & Priftis, K. (2001). Prevalence of asthma among schoolchildren in Patras, Greece: Three surveys over 20 years. Thorax, 56(7), 569–571.

Premal Thaker | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Premal Thaker | Clinical Trials | Best Researcher Award

Dr. Premal Thaker at Washington University School of Medicine, United States.

Dr. Premal Thaker is a renowned gynecologic oncologist and professor at Washington University, St. Louis. With a medical degree from Allegheny University and advanced training at MD Anderson Cancer Center, she has led impactful clinical research in ovarian and endometrial cancers 🧪. As Director of Gynecologic Oncology Clinical Research and Division Chief (2025–present), her leadership is pivotal in advancing cancer therapies. A respected speaker, grant recipient, and editorial board member 📚, Dr. Thaker has earned numerous accolades including “Best Doctors in America” and “Castle Connolly Top Doctor” 🏅. Her dedication to women’s health continues to inspire globally.

Publication Profile 

Scopus

Education

Dr. Premal Thaker’s illustrious academic journey began with a BA in Biology from Villanova University 🎓, followed by an MD from Allegheny University and an MS in Cancer Biology from the University of Texas 🧬. She completed specialized training in gynecologic oncology at MD Anderson Cancer Center and recently attended a leadership course at Harvard 🏛️. Dr. Thaker has held esteemed positions at Washington University, advancing from Assistant Professor to Division Chief of Gynecologic Oncology 👩‍⚕️. A distinguished researcher and educator, she is also the David and Lynn Mutch Distinguished Professor and Director of Clinical Research.

Awards

Dr. Premal Thaker has received numerous accolades throughout her distinguished career in gynecologic oncology 🎖️. Beginning with academic honors such as the Dean’s List and Alpha Epsilon Delta Honor Society in the early 1990s 📚, she went on to earn prestigious awards for scientific presentations and publications, including the J.G. Moore Award 🧪 and GCF/Eli Lilly Fellow Award 🧬. Recognized as one of the Best Doctors in St. Louis (2013–2025) and America (2020–2024) 👩‍⚕️, she was also named a Castle Connolly Top Doctor and Fellow of AGOS. In 2025, she joined Avant-Garde Health’s Research All-Stars.

Research Focus 

Dr. Premal Thaker’s research primarily centers on gynecologic oncology, with a strong focus on ovarian and endometrial cancers 🧫. Her work explores immune checkpoint inhibitors, personalized gene therapy, molecular profiling, and health disparities in clinical trial enrollment, particularly in Hispanic and Asian populations 🌍. She also investigates novel immunotherapy combinations, real-world treatment outcomes, and genomic biomarkers for therapy response and survival 🧪. Her multidisciplinary efforts contribute to precision medicine and the advancement of targeted therapies for women’s reproductive cancers, driving impactful, patient-centered innovations in oncology care.

Publication Top Notes

  • Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel
  • OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer
  • Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial
  • Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study
  • Diverse case series of granulomatous peritonitis mimicking advanced ovarian cancer
  • Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study
  • Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis
  • Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer
  • Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma
  • Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study

Golgem Mehmetoglu | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Golgem Mehmetoglu | Clinical Trials | Best Researcher Award

Ms. Golgem Mehmetoglu, European University of Lefke, Cyprus

Ms. Gölgem Mehmetoğlu is a dedicated physiotherapist and academic specializing in Physiotherapy and Rehabilitation. 🎓 She earned her B.Sc. from Eastern Mediterranean University (2011–2015), her M.Sc. from European University of Lefke (2015–2017), and is currently pursuing her Ph.D. at EMU. 🧠 Her research focuses on muscle function, postural stability, and rehabilitation outcomes, with multiple publications in international journals and conference proceedings. 📝 She also teaches core courses such as Kinesiology, Biomechanics, and Manual Therapy Techniques. 👩‍🏫 Her scientific contributions and educational roles make her a valuable candidate for the Best Researcher Award.

Publication Profile

Orcid

Education

Ms. Gölgem Mehmetoğlu is a passionate professional in the field of Physiotherapy and Rehabilitation 🧘‍♀️. She completed her undergraduate studies (2011–2015) at Doğu Akdeniz University 🏛️, laying a strong foundation in clinical practice and patient care. She then pursued her Master’s degree (2015–2017) at Lefke Avrupa University 📘, deepening her knowledge in rehabilitation science. Currently, she is advancing her academic journey through a Ph.D. program at Doğu Akdeniz University (2018–present) 🧪. Her academic path reflects commitment to continuous learning and specialization in physiotherapy, contributing to healthcare with evidence-based practice and innovative research.

Academic Positions

Ms. Golgem Mehmetoğlu 🎓 is a dedicated academic in the field of physiotherapy and rehabilitation, actively engaged in teaching at the undergraduate level. She shares her expertise through a variety of core courses including Kinesiology 🤸‍♀️, Biomechanics 🦴, Normal Motor Development 🧠, and Manual Therapy Techniques (Manipulation-Mobilization I & II) 💆‍♀️. Her teaching approach combines theoretical knowledge with hands-on application, empowering students with essential clinical and analytical skills. Through her passionate involvement in education, Ms. Mehmetoğlu continues to inspire future healthcare professionals and contribute meaningfully to the advancement of physiotherapy science.

Research Focus

Ms. Gölgem Mehmetoğlu’s 🔬 research primarily focuses on musculoskeletal rehabilitation, particularly addressing chronic pain, posture correction, functional mobility, and manual therapy in physiotherapy patients. Her studies emphasize the impact of stabilization exercises 🧘‍♀️ on pain relief, posture (craniovertebral angle 📐), disability reduction, and quality of life 🌿 in conditions like chronic neck pain and lateral epicondylitis. Her work explores the integration of exercise science, biomechanics 🤸, and evidence-based physiotherapy to improve patient outcomes. Through randomized controlled trials and clinical interventions, she contributes valuable knowledge to rehabilitation sciences and therapeutic exercise interventions.

Publication Top Notes

Effect of Postural Stabilization Exercises in Combination with Cervical Stabilization Exercises on Craniovertebral Angle, Pain, Disability, and Quality of Life in Patients with Chronic Neck Pain: A Randomized Controlled Trial

The Effects of Muscle Strength and Muscle Endurance on Upper Extremity Functions of Lateral Epicondylitis Patients

The Pain in the Canon of Medicine: Types, Causes, and Treatment

Zhumin Cao | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Zhumin Cao | Clinical Trials | Best Researcher Award

Prof. Zhumin Cao, The Seventh People’s Hospital of Chongqing, China

Prof. Zhumin Cao is a dedicated clinician and researcher in vascular diseases 🫀, with extensive experience in both basic and clinical research. He has served as a Visiting Scholar at Ajoy University Hospital 🇰🇷 and Carl Gustav Carus University Hospital 🇩🇪. Prof. Cao has led five funded research projects and published 20+ papers, including 10+ SCI articles with a cumulative impact factor of 40+ 📊. His current focus is on early intracavitary treatment of pulmonary embolism, pioneering innovations in patient care. He is also a reviewer for Angiology and Frontiers 📝.

Publication Profile

Scopus

Education

Prof. Zhumin Cao has dedicated his career to clinical and basic research in vascular diseases 🫀. He has served as a Visiting Scholar at Ajoy University Hospital in South Korea 🇰🇷 and University Hospital Carl Gustav Carus in Germany 🇩🇪. His leadership includes two provincial and three departmental-level projects 📊. He actively contributes to the scientific community as a peer reviewer for Angiology and Frontiers 📝. Prof. Cao has authored over 20 research papers, including 10+ SCI-indexed publications, with a combined impact factor of 40+, and a single article IF reaching 11.4 🌟.

Areas of Research

Prof. Zhumin Cao specializes in the field of vascular diseases 🫀, with a primary research focus on the early treatment of pulmonary embolism 🫁—a life-threatening and time-sensitive condition that poses significant challenges in clinical practice ⏱️. His work aims to improve therapeutic strategies and patient outcomes through intracavitary interventions and innovative approaches in vascular care 💉. By bridging clinical application and basic research, Prof. Cao’s studies contribute meaningfully to the development of evidence-based practices in cardiovascular medicine 🌍. His dedication supports advancements in critical care and interventional procedures that save lives every day ❤️.

Research Focus

Prof. Zhumin Cao’s research delves into the role of Interleukin-6 (IL-6) in reshaping the tumor microenvironment 🧫, a key factor in cancer progression and resistance to therapy. His work explores how IL-6-driven changes affect immune cell behavior and tumor dynamics 🧬. By understanding this cytokine’s influence, he aims to enhance the effectiveness of cancer immunotherapy 💉, offering new avenues for targeted treatments. This research bridges oncology and immunology, contributing to breakthroughs in precision medicine 🧠. Prof. Cao’s findings could lead to improved outcomes for patients battling aggressive cancers through innovative immunomodulatory strategies 🎯.

Publication Top Notes

Interleukin-6 (IL-6)-associated tumor microenvironment remodelling and cancer immunotherapy